Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Finished Goods (2017 - 2024)

RedHill Biopharma has reported Finished Goods over the past 8 years, most recently at $2.8 million for Q4 2024.

  • Quarterly Finished Goods fell 14.96% to $2.8 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2024, down 14.96% year-over-year, with the annual reading at $2.8 million for FY2024, 14.96% down from the prior year.
  • Finished Goods was $2.8 million for Q4 2024 at RedHill Biopharma, down from $3.3 million in the prior quarter.
  • Over five years, Finished Goods peaked at $6.8 million in Q4 2022 and troughed at $2.8 million in Q4 2024.
  • The 5-year median for Finished Goods is $4.7 million (2020), against an average of $4.9 million.
  • Year-over-year, Finished Goods soared 1521.23% in 2020 and then tumbled 51.25% in 2023.
  • A 5-year view of Finished Goods shows it stood at $4.7 million in 2020, then soared by 39.48% to $6.6 million in 2021, then grew by 3.39% to $6.8 million in 2022, then tumbled by 51.25% to $3.3 million in 2023, then dropped by 14.96% to $2.8 million in 2024.
  • Per Business Quant, the three most recent readings for RDHL's Finished Goods are $2.8 million (Q4 2024), $3.3 million (Q4 2023), and $6.8 million (Q4 2022).